AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9164223 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2 on day 1) and Etoposide (80 mg/m2 on days 1, 2, and 3 of each 28‐day cycle)
Number of subjects: 53
Study 9164223 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM)
Number of subjects: 53
Study 9164223 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and Etoposide (EP)
Number of subjects: 53
Study 7524907 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (filgrastim 5 micrograms/kg/day) administered prior to and after PBSC reinjection
Number of subjects: 23
Study 7524907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G‐CSF prior to leukaphereses or after high‐dose therapy)
Number of subjects: 23
Study 7524907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (G‐CSF and control)
Number of subjects: 23
Study 7524907 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 23
Study 3109764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (rt-PA) 80 mg (40 mg, 20 mg, and 20 mg in successive hours)
Number of subjects: 290
Study 3109764 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase (SK) 1.5 million units over 1 hr
Number of subjects: 290
Study 3109764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (rt-PA)
Number of subjects: 290
Study 3109764 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase (SK)
Number of subjects: 290
Study 3109764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rt-PA and SK
Number of subjects: 290
Study 29072478 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of sensation seeking and perceived peer drinking
Number of subjects: 3287
Study 29072478 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality profiles of impulsivity, sensation seeking, and hopelessness
Number of subjects: 3287
Study 29072478 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 3287
Study 28345121 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person genomic counseling (intervention arm, n=98)
Number of subjects: 199
Study 28345121 — intervention group
Group type: COMPARATOR
Intervention: Control (control arm, n=101)
Number of subjects: 199
Study 26291080 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg E-52862
Number of subjects: 32
Study 26291080 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg E-52862
Number of subjects: 32
Study 26291080 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg E-52862
Number of subjects: 32
Study 26291080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26291080 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised meal
Number of subjects: 32
Study 23756360 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1445
Study 23756360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) plus Tamoxifen
Number of subjects: 1445
Study 20628233 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid infusions (monthly, bi-monthly, tri-monthly, or semestral)
Number of subjects: 95
Study 20628233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 95
Study 18641498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociograms used in focus group analysis
Number of subjects: 0
Study 18641498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociograms
Number of subjects: 0
Study 16844628 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCP with pressure control (group 1)
Number of subjects: 62
Study 16844628 — intervention group
Group type: COMPARATOR
Intervention: ASCP with flow control (group 2)
Number of subjects: 62
Study 12728462 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine restriction (less than 100 micro g/day)
Number of subjects: 45
Study 12728462 — intervention group
Group type: COMPARATOR
Intervention: Iodine non-restriction
Number of subjects: 45
Study 10915728 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta (6 million units, twice a week for 36 months)
Number of subjects: 20
Study 10915728 — intervention group
Group type: COMPARATOR
Intervention: No IFN therapy (control group)
Number of subjects: 20
Study 8725871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergoset (1.6-2.4 mg/day)
Number of subjects: 17
Study 8725871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1483671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg in saline solution
Number of subjects: 30
Study 1483671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg in saline solution
Number of subjects: 30
Study 1483671 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 30
Study 6198910 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/MOPP/ABV/radiotherapy
Number of subjects: 71
Study 6198910 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP/ABV plus dacarbazine (D)
Number of subjects: 71
Study 31588504 — intervention group
Group type: EXPERIMENTAL
Intervention: >10% weight loss
Number of subjects: 10081
Study 31588504 — intervention group
Group type: COMPARATOR
Intervention: Stable weight
Number of subjects: 10081
Study 30473097 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3298176 10 mg
Number of subjects: 142
Study 30473097 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3298176 15 mg
Number of subjects: 142
Study 30473097 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3298176 1.5 mg
Number of subjects: 142
Study 30473097 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3298176 4.5 mg
Number of subjects: 142
Study 30473097 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide (DU)
Number of subjects: 142
Study 30473097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 27225316 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA‐rich fish oil capsules (800 mg/d DHA and 100 mg/d EPA)
Number of subjects: 706
Study 24316517 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin 500 mg t.i.d. for 7 days
Number of subjects: 20
Study 24316517 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 500 mg t.i.d. for 7 days
Number of subjects: 20
Study 22356596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) group
Number of subjects: 245
Study 22356596 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-experiential therapy (SET) group
Number of subjects: 245
Study 22356596 — intervention group
Group type: COMPARATOR
Intervention: Educational level as a predictor
Number of subjects: 245
Study 20504210 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline monotherapy
Number of subjects: 398
Study 20504210 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline therapy
Number of subjects: 398
Study 18561718 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of ciprofloxacin given 24 hours before return
Number of subjects: 797
Study 18561718 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (group 1, no intervention)
Number of subjects: 797
Study 15991508 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine + 3 mg kg(‐1) lidocaine
Number of subjects: 40
Study 15991508 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 mg kg(‐1) lidocaine diluted with saline)
Number of subjects: 40
Study 14602752 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH (100 microg)
Number of subjects: 50
Study 14602752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11030676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography with Alvarado score
Number of subjects: 302
Study 11030676 — intervention group
Group type: COMPARATOR
Intervention: Control (clinical diagnosis)
Number of subjects: 302
Study 8854194 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol
Number of subjects: 3854
Study 8854194 — intervention group
Group type: COMPARATOR
Intervention: reference
Number of subjects: 3854
Study 1468786 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program involving video workshops and contests on AIDS.
Number of subjects: 0
Study 6541533 — intervention group
Group type: COMPARATOR
Intervention: High-dose dexamethasone (DXM) (regimen A)
Number of subjects: 24
Study 6541533 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DXM and high doses of metoclopramide (MCP) (regimen B)
Number of subjects: 24
Study 31591408 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced CT
Number of subjects: 0
Study 31591408 — intervention group
Group type: COMPARATOR
Intervention: Enhanced CT
Number of subjects: 0
Study 30381011 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 144
Study 30381011 — intervention group
Group type: COMPARATOR
Intervention: Sham TEAS
Number of subjects: 144
Study 27694568 — intervention group
Group type: EXPERIMENTAL
Intervention: Early food supplementation (608 kcal)
Number of subjects: 1667
Study 27694568 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS)
Number of subjects: 1667
Study 27694568 — intervention group
Group type: COMPARATOR
Intervention: 60 mg iron and 400 μg folic acid
Number of subjects: 1667
Study 23867040 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation with mirror therapy (FES with MT)
Number of subjects: 23
Study 23867040 — intervention group
Group type: COMPARATOR
Intervention: Functional electrical stimulation without mirror therapy (FES without MT)
Number of subjects: 23
Study 22314470 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (n=50)
Number of subjects: 100
Study 22314470 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 100
Study 21077775 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 1642
Study 21077775 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 1642
Study 21077775 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Circumference (HC)
Number of subjects: 1642
Study 21077775 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Number of subjects: 1642
Study 21077775 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC) and Hip Circumference (HC)
Number of subjects: 1642
Study 18004207 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (125 microg/kg)
Number of subjects: 29
Study 18004207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11059968 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with nonischemic CHF
Number of subjects: 199
Study 9086977 — intervention group
Group type: EXPERIMENTAL
Intervention: Learned resourcefulness training (LRT)
Number of subjects: 37
Study 9086977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8443027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 76
Study 8443027 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 76
Study 8443027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 76
Study 3529351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential female sex hormones and/or 1,25(OH)2D3, 0.25 microgram per day
Number of subjects: 186
Study 3529351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 29352461 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic L. reuteri lozenge (1 lozenge daily for 30 days)
Number of subjects: 44
Study 29352461 — intervention group
Group type: COMPARATOR
Intervention: Mechanical therapy alone (Control)
Number of subjects: 44
Study 29352461 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic L. reuteri lozenge
Number of subjects: 44
Study 27197100 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard polymeric diet
Number of subjects: 23
Study 27197100 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 23
Study 24323244 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity behavioral intervention delivered via the Internet and one-on-one video chat sessions with a behavior-change coach.
Number of subjects: 82
Study 24323244 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition.
Number of subjects: 82
Study 22189052 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone plus brief individual counseling
Number of subjects: 122
Study 22189052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 20724057 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (4‐h immersive simulation course in CPR leadership)
Number of subjects: 32
Study 20724057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 32
Study 20724057 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 32
Study 20724057 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 18536619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib‐MenC‐TT booster dose
Number of subjects: 358
Study 18536619 — intervention group
Group type: COMPARATOR
Intervention: DTPa‐HBV‐IPV/Hib control
Number of subjects: 358
Study 15452683 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg/70 kg)
Number of subjects: 18
Study 15452683 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg/70 kg, intravenously administered)
Number of subjects: 18
Study 15452683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12867520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively impaired patients
Number of subjects: 0
Study 12867520 — intervention group
Group type: COMPARATOR
Intervention: Cognitively unimpaired patients
Number of subjects: 0
Study 10378917 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT; N = 14)
Number of subjects: 21
Study 10378917 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; N = 7)
Number of subjects: 21
Study 10378917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RT and CON)
Number of subjects: 21
Study 10064355 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine phosphate-enriched cardioplegic solution (group I)
Number of subjects: 40
Study 10064355 — intervention group
Group type: COMPARATOR
Intervention: Standard cardioplegic solution (group II)
Number of subjects: 40
Study 1838923 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril (ACE inhibitor)
Number of subjects: 16
Study 1838923 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 27859897 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and telephone counseling program
Number of subjects: 102
Study 27859897 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (Control)
Number of subjects: 102
Study 25768849 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg/d (with possible adjustment to 40 mg/d)
Number of subjects: 308
Study 25768849 — intervention group
Group type: COMPARATOR
Intervention: Istradefylline 20 mg/d and 40 mg/d (previously taken in double-blind study)
Number of subjects: 308
Study 24358296 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 100 and/or 200 micrograms/m(3) particulate matter
Number of subjects: 43
Study 24358296 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 43
Study 21221666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc replacement (arthroplasty)
Number of subjects: 20
Study 21221666 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (fusion)
Number of subjects: 20
Study 21221666 — intervention group
Group type: COMPARATOR
Intervention: Comparison of adjacent segments between both groups
Number of subjects: 20
Study 21221666 — intervention group
Group type: COMPARATOR
Intervention: Clinical results for both groups
Number of subjects: 20
Study 19478653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular oxygen-ozone (O2O3) therapy
Number of subjects: 60
Study 19478653 — intervention group
Group type: COMPARATOR
Intervention: Simulated therapy (control)
Number of subjects: 60
Study 18389665 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-activated autologous platelet-rich plasma (PRP) applied in 50 patients.
Number of subjects: 100
Study 18389665 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 patients) who underwent AAA EVAR without PRP.
Number of subjects: 100
Study 16048250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glucose degradation product (GDP) dialysis solution
Number of subjects: 60
Study 12199409 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening practice with natural speech
Number of subjects: 0
Study 12199409 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening practice with DECtalk synthesized speech
Number of subjects: 0
Study 12199409 — intervention group
Group type: COMPARATOR
Intervention: Comparison of natural speech and DECtalk synthesized speech
Number of subjects: 0
Study 10073749 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg single dose)
Number of subjects: 150
Study 10073749 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily for at least 1 week)
Number of subjects: 150
Study 7633860 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal intensive care technology
Number of subjects: 0
Study 7633860 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized networks of neonatal intensive care units
Number of subjects: 0
Study 2043179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of quinine sulfate plus theophylline ethylene diamine (CTED)
Number of subjects: 164
Study 2043179 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 164
Study 2043179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 2043179 — intervention group
Group type: EXPERIMENTAL
Intervention: CTED group (n = 34)
Number of subjects: 164
Study 2043179 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 40)
Number of subjects: 164
Study 2043179 — intervention group
Group type: COMPARATOR
Intervention: Quinine group (n = 43)
Number of subjects: 164
Study 6756775 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 alone (Group A, 232 patients)
Number of subjects: 400
Study 6756775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior intracervical laminaria insertion (Group B, 106 patients)
Number of subjects: 400
Study 6756775 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria and continuous intravenous oxytocin infusion (Group C, 62 patients)
Number of subjects: 400
Study 6756775 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 400
Study 31302802 — intervention group
Group type: EXPERIMENTAL
Intervention: Action and coping planning intervention (20-min session)
Number of subjects: 184
Study 31302802 — intervention group
Group type: COMPARATOR
Intervention: Assessment alone (Control)
Number of subjects: 184
Study 31302802 — intervention group
Group type: EXPERIMENTAL
Intervention: Action and coping planning intervention
Number of subjects: 184
Study 27784409 — intervention group
Group type: EXPERIMENTAL
Intervention: cb‐CBT‐I (computer-based cognitive behavioral therapy for insomnia)
Number of subjects: 34
Study 27784409 — intervention group
Group type: COMPARATOR
Intervention: Sleep diary group (active control)
Number of subjects: 34
Study 26459645 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome on
Number of subjects: 155
Study 26459645 — intervention group
Group type: COMPARATOR
Intervention: Metronome off
Number of subjects: 155
Study 26459645 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome on (medical students)
Number of subjects: 155
Study 26459645 — intervention group
Group type: COMPARATOR
Intervention: Metronome off (medical students)
Number of subjects: 155
Study 26459645 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome on (pediatric residents and fellows)
Number of subjects: 155
Study 26459645 — intervention group
Group type: COMPARATOR
Intervention: Metronome off (pediatric residents and fellows)
Number of subjects: 155
Study 26459645 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome on (pediatric nurses)
Number of subjects: 155
Study 26459645 — intervention group
Group type: COMPARATOR
Intervention: Metronome off (pediatric nurses)
Number of subjects: 155
Study 22889920 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure sealant with primer and bond (3M Scotchbond Multi‐Purpose Plus System primer and bond)
Number of subjects: 78
Study 22889920 — intervention group
Group type: COMPARATOR
Intervention: Fissure sealant without primer and bond (Delton Plus)
Number of subjects: 78
Study 21487863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine injection
Number of subjects: 68
Study 21487863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine instillation
Number of subjects: 68
Study 21487863 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo control)
Number of subjects: 68
Study 19637428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 0
Study 19637428 — intervention group
Group type: COMPARATOR
Intervention: Adefovir
Number of subjects: 0
Study 17922738 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol therapy for 12 weeks
Number of subjects: 20
Study 17922738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 14994363 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming therapy (heating vest set to medium heat for 3 hours a day for 21 days)
Number of subjects: 21
Study 14994363 — intervention group
Group type: COMPARATOR
Intervention: Control (heating vest set to off for 3 hours a day for 21 days)
Number of subjects: 21
Study 11679149 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 MN rgp160 ImmunoAG vaccine
Number of subjects: 22
Study 11679149 — intervention group
Group type: COMPARATOR
Intervention: Highly active antiretroviral therapy (HAART) (ritonavir, didanosine, and stavudine)
Number of subjects: 22
Study 9355055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ariel 5000
Number of subjects: 41